https://allsci.com/news/regulatory/kt501-fda-clearance-kali-therapeutics-receives/ AllScien 2026-09-03T16:11:11.073131Z Kali, Sanofi's tri-specific T-cell engager cleared for US study in rheumatoid arthritis https://allsci.com/news/regulatory/gene-therapy-hearing-loss-france-clears/ AllScien 2026-09-03T15:39:15.473310Z France clears Sensorion's gene therapy SENS-601 into human testing for GJB2 hearing loss https://allsci.com/news/licensing-and-partnerships/bofanglutide-menarini-deal-gan-lee-licenses-to/ AllScien 2026-09-03T14:58:03.006269Z Menarini puts up EUR 726M for Euro rights to Gan & Lee’s biweekly GLP-1 https://allsci.com/news/clinical-trials/rasonque-ras-mutant-lung-cancer-revolution/ AllScien 2026-09-03T12:36:05.994221Z NEJM publishes daraxonrasib NSCLC data supporting Phase III program https://allsci.com/news/regulatory/hs-20093-small-cell-lung-cancer-nmpa-accepts/ AllScien 2026-09-03T12:04:57.759657Z NMPA accepts Hansoh’s B7-H3 ADC HS-20093 in post-platinum SCLC https://allsci.com/news/grants/mrna-manufacturing-grant-waterfall-scientific/ AllScien 2026-09-03T10:01:26.588289Z ARPA-H backs Waterfall Scientific-led mRNA manufacturing platform with up to USD 54.5m https://allsci.com/news/clinical-trials/ivonescimab-keytruda-lung-cancer-akesos-beats/ AllScien 2026-09-03T09:54:43.123409Z Akeso's ivonescimab beats Keytruda on overall survival in advanced NSCLC https://allsci.com/news/licensing-and-partnerships/gsk-hutchmed-kras-egfr-deal-pays-usd-110m-upfront/ AllScien 2026-09-03T09:36:02.694722Z GSK bets USD 1.3b on HutchMed's KRAS-EGFR conjugate https://allsci.com/news/clinical-trials/apazunersen-angelman-syndrome-trial-ultragenyxs/ AllScien 2026-09-03T09:16:33.391133Z Ultragenyx’s Angelman setback puts UBE3A strategy under scrutiny https://allsci.com/news/corporate-strategy/tscan-therapeutics-restructuring-abandons/ AllScien 2026-09-03T09:01:52.605032Z TScan restructures around in vivo TCR-T, pauses Phase III hematology program https://allsci.com/news/grants/usp30-inhibitor-acute-kidney-injury-vincere/ AllScien 2026-09-02T18:39:19.541249Z Vincere Bio wins grant for USP30 inhibitor IND-enabling studies in acute kidney injury https://allsci.com/news/grants/endometriosis-pain-treatment-boston-childrens/ AllScien 2026-09-02T18:32:40.902504Z Boston Children's Hospital picks up USD 3.9m NIH grant to target endometriosis pain via lipid receptors https://allsci.com/news/grants/engineered-treg-therapy-type-1-diabetes/ AllScien 2026-09-02T18:30:11.671494Z GentiBio secures NIH backing for allogeneic engineered Treg therapy in type 1 diabetes https://allsci.com/news/regulatory/avacopan-suspension-mhra-suspends-authorization/ AllScien 2026-09-02T18:19:26.125011Z Taveos' unraveling accelerates as UK joins global regulatory retreat https://allsci.com/news/licensing-and-partnerships/owkin-k-pro-ai-platform-boehringer-ingelheim/ AllScien 2026-09-02T18:02:51.114757Z Boehringer Ingelheim licenses Owkin's K Pro AI platform and immunology data https://allsci.com/news/funding/leronlimab-cancer-funding-cytodyn-secures-usd/ AllScien 2026-09-02T17:51:46.214069Z CytoDyn bags another USD 16.5m in PIPE deal to support CCR5-targeted leronlimab https://allsci.com/news/licensing-and-partnerships/vhh-antibody-license-neuroscience-biocytogen/ AllScien 2026-09-02T17:42:13.479462Z Biocytogen grants Qilu non-exclusive license to preclinical VHH antibody for neuroscience https://allsci.com/news/venture-financing/car-t-gene-therapy-typewriter-therapeutics/ AllScien 2026-09-02T17:37:50.868768Z Typewriter emerges with USD 56m to build non-viral in vivo CAR-T platform https://allsci.com/news/licensing-and-partnerships/novartis-alteogen-license-agreement-licenses/ AllScien 2026-09-02T17:30:31.137020Z Novartis taps Alteogen in USD 3.2b subcutaneous biologics pact https://allsci.com/news/licensing-and-partnerships/stapokibart-license-asia-keymed-licenses-approved/ AllScien 2026-09-02T17:24:58.438052Z Keymed licenses approved IL-4Ralpha mAb stapokibart to Singapore firm Aeira for 18 Asian markets https://allsci.com/news/clinical-trials/car-t-prostate-cancer-trial-adicet-initiates/ AllScien 2026-09-02T15:34:58.224607Z Adicet preps off-the-shelf gamma delta CAR-T for first-in-human prostate cancer study https://allsci.com/news/licensing-and-partnerships/egfr-inhibitor-lung-cancer-pharos-ibio-and-kolon/ AllScien 2026-09-02T15:09:18.917112Z Korea's Pharos iBio, Kolon Pharma advance fourth-generation EGFR inhibitor into preclinical https://allsci.com/news/regulatory/amt-130-gene-therapy-huntingtons-uniqure-files/ AllScien 2026-09-02T15:07:32.078379Z uniQure files AMT-130 BLA after stop-start FDA path https://allsci.com/news/licensing-and-partnerships/ai-regulatory-automation-drug-development/ AllScien 2026-09-02T14:39:57.376841Z Takeda taps Weave Bio for AI regulatory automation across 14 drug programs https://allsci.com/news/clinical-trials/psma-targeted-therapy-clinical-trial-norroy/ AllScien 2026-09-02T14:34:09.067887Z Norroy advances first domestically developed PSMA-targeted therapy into pivotal China trial https://allsci.com/news/research/prime-editing-genomic-dna-integration-seoul/ AllScien 2026-09-02T14:22:13.747920Z Seoul team extends prime editing to large-scale DNA replacement https://allsci.com/news/research/cystic-fibrosis-trna-treatment-university-of/ AllScien 2026-09-02T14:09:50.835401Z University of Toronto, SickKids develop chemically modified tRNA platform for cystic fibrosis nonsense mutations https://allsci.com/news/clinical-trials/mrna-flu-vaccine-gsks-tops-standard-and-high-dose/ AllScien 2026-09-02T13:19:39.392619Z GSK advances dual-antigen mRNA flu vaccine to Phase III after positive Phase II https://allsci.com/news/clinical-trials/celiac-disease-treatment-antibody-tevas/ AllScien 2026-09-02T12:59:38.639223Z Teva's anti-IL-15 antibody cuts gluten-induced intestinal damage in Phase IIa celiac disease trial https://allsci.com/news/clinical-trials/rzl-012-phase-iii-submental-fat-raziels-meets/ AllScien 2026-09-02T11:53:57.289935Z Raziel's RZL-012 meets Phase III endpoints for submental fat reduction, paving China NDA path https://allsci.com/news/corporate-strategy/vertex-crinetics-acquisition-closes-usd-10b-deal/ AllScien 2026-09-02T11:42:47.858580Z Vertex closes USD 10b Crinetics deal to establish endocrinology as fifth therapeutic pillar https://allsci.com/news/first-in-human-trials/cdh17-antibody-gastric-cancer-bighats-ai-designed/ AllScien 2026-09-02T11:39:04.457274Z BigHat's AI-designed CDH17 antibody enters human testing for gastric cancer https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-neurological-ono-pharma-taps/ AllScien 2026-09-02T11:20:56.668471Z Ono Pharma taps Aitia's causal AI to identify neurological disease targets https://allsci.com/news/licensing-and-partnerships/t-cell-engager-therapy-solid-tumors-evotec-and/ AllScien 2026-09-02T10:53:26.491570Z Evotec and Plectonic combine T-cell platforms to tackle solid tumor selectivity challenge https://allsci.com/news/regulatory/fda-breakthrough-hypoxia-cancer-junipers-tracer/ AllScien 2026-09-01T18:11:21.836076Z FDA grants breakthrough status to Juniper hypoxia tracer for radiation de-escalation in HPV-positive OPC https://allsci.com/news/clinical-trials/gene-therapy-geographic-atrophy-ocugen-launches/ AllScien 2026-09-01T18:07:46.507638Z Ocugen launches Phase III trial of one-time gene therapy for geographic atrophy https://allsci.com/news/clinical-trials/envudeucitinib-lupus-trial-fails-phase-iib-but/ AllScien 2026-09-01T18:03:42.079676Z Envudeucitinib misses Phase IIb lupus endpoints, subgroup signal keeps program alive https://allsci.com/news/clinical-trials/remibrutinib-multiple-sclerosis-novartiss-beats/ AllScien 2026-09-01T18:01:31.831597Z Novartis's remibrutinib beats teriflunomide across Phase III relapsing MS trials https://allsci.com/news/clinical-trials/biontech-colorectal-cancer-trial-terminates/ AllScien 2026-09-01T17:30:07.053894Z BioNTech halts personalized mRNA cancer vaccine trial in CRC after survival imbalance